title: [Thyroid transcription factor-1 level is associated with epidermal growth factor receptor mutation status in patients with advanced lung adenocarcinoma].
abstract: OBJECTIVE
  Epidermal growth factor receptor (EGFR) mutation status plays an important role in individual treatment of non-small cell lung cancer.However clinical tissue samples for mutation detection are not always available in advanced NSCLC. Thus an alternative method of EGFR mutation detection is required in NSCLC treatment.Recent studies have associated thyroid transcription factor 1 (TTF-1) with EGFR mutations in lung cancer.In this study, we detected expression of TTF-1 and EGFR mutations in 102 patients with advanced NSCLC and investigated the possibility of TTF-1 as a potential indicator of EGFR status.
  
  
  METHODS
  Serum and tissue samples were collected from 102 patients with advanced NSCLC including 28 cases of EGFR mutation in 19 exon, 23 cases of EGFR mutation in 21 exon and 51 cases of WT EGFR. Protein levels of TTF-1 in serum were quantified by enzyme-linked immunosorbent assay (ELISA).Levels of TTF-1 in tissues were detected by immunohistochemistry (IHC). SPSS 17 statistical software was used to analyze the data.
  
  
  RESULTS
  In the serum the expression of TTF-1 in EGFR 19 and 21 exon MT groups both was higher than that in the WT group(19MT vs 21MT vs WT: 0.092 vs 0.083 vs 0.045; F = 27.653, P < 0.01), and the result of the tissues was the same (19MT vs 21MT vs WT: 0.682 vs 0.644 vs 0.441; F = 47.665, P < 0.01), but no differences between two MT groups were observed (P > 0.05). The ELISA results and the IHC results were consistent (r = 0.87, P < 0.01). The expression of TTF-1 in serum showed a relationship with smoking history (χ² = 4.639, P < 0.05), but not with sex, age, TNM stage and metastasis (P > 0.05).
  
  
  CONCLUSIONS
  These results indicated that TTF-1 expression was upregulated in EGFR mutated NSCLC compared to EGFR WT NSCLC. The level of TTF-1 maybe used as a potential marker of EGFR mutation status.
authors.affiliation: Department of Respiratory Medicine, Department of Pathology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Niu
authors.forename: Huijuan
authors.initials: H
authors.lastname: Wang
authors.forename: Guowei
authors.initials: G
authors.lastname: Zhang
authors.forename: Jie
authors.initials: J
authors.lastname: Ma
authors.forename: Bing
authors.initials: B
authors.lastname: Wei
authors.affiliation: Email: mazhiyong@csco.org.cn.
authors.forename: Zhiyong
authors.initials: Z
authors.lastname: Ma
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics*; D000077192:Adenocarcinoma of Lung; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics*; D004797:Enzyme-Linked Immunosorbent Assay; D066246:ErbB Receptors / Q000235:genetics*; D005091:Exons; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000235:genetics*; D009154:Mutation; D009687:Nuclear Proteins / Q000235:genetics*; D012737:Sex Factors; D013961:Thyroid Gland; D000074482:Thyroid Nuclear Factor 1; D014157:Transcription Factors / Q000235:genetics*
chemical_list: C000614412:NKX2-1 protein, human; D009687:Nuclear Proteins; D000074482:Thyroid Nuclear Factor 1; D014157:Transcription Factors; D066246:ErbB Receptors